Association of Renin-Angiotensin Inhibitor Treatment with Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement

Taku Inohara, Pratik Manandhar, Andrzej S. Kosinski, Roland A. Matsouaka, Shun Kosaka, Robert J. Mentz, Vinod H. Thourani, John D. Carroll, Ajay J. Kirtane, Joseph E. Bavaria, David J. Cohen, Todd L. Kiefer, Jeffrey G. Gaca, Samir R. Kapadia, Eric D. Peterson, Sreekanth Vemulapalli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Importance Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function. Objective To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR. Design, Setting, and Participants Retrospective cohort study of TAVR procedures performed in the United States (using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry) between July 2014 and January 2016 that were linked to Medicare claims data (final date of follow-up: March 31, 2017). To account for differences in demographics, echocardiographic findings, and in-hospital complications, 1:1 propensity matching was performed. Exposures Initial hospital discharge prescription of a RAS inhibitor after TAVR. Main Outcomes and Measures Primary outcomes were all-cause death and readmission due to heart failure at 1 year after discharge, which were considered separately. The secondary outcome was health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ; score range: 0-100, with a higher score indicating less symptom burden and better quality of life; a small effect size was defined as 5 points) at 1 year. Results Among 21312 patients who underwent TAVR at 417 US sites, 8468 patients (39.7%) were prescribed a RAS inhibitor at hospital discharge. After propensity matching, 15896 patients were included (mean [SD] age, 82.4 [6.8] years; 48.1% were women; mean [SD] left ventricular ejection fraction [LVEF], 51.9% [11.5%]). Patients with a prescription for a RAS inhibitor vs those with no prescription had lower mortality rates at 1 year (12.5% vs 14.9%, respectively; absolute risk difference [ARD], -2.4% [95% CI, -3.5% to -1.4%]; hazard ratio [HR], 0.82 [95% CI, 0.76 to 0.90]) and lower heart failure readmission rates at 1 year (12.0% vs 13.8%; ARD, -1.8% [95% CI, -2.8% to -0.7%]; HR, 0.86 [95% CI, 0.79 to 0.95]). When stratified by LVEF, having a prescription for a RAS inhibitor vs no prescription was associated with lower 1-year mortality among patients with preserved LVEF (11.1% vs 13.9%, respectively; ARD, -2.81% [95% CI, -3.95% to -1.67%]; HR, 0.78 [95% CI, 0.71 to 0.86]), but not among those with reduced LVEF (18.8% vs 19.5%; ARD, -0.68% [95% CI, -3.52% to 2.20%]; HR, 0.95 [95% CI, 0.81 to 1.12]) (P =.04 for interaction). Of 15896 matched patients, 4837 (30.4%) were included in the KCCQ score analysis and improvements at 1 year were greater in patients with a prescription for a RAS inhibitor vs those with no prescription (median, 33.3 [interquartile range, 14.2 to 51.0] vs 31.3 [interquartile range, 13.5 to 51.1], respectively; difference in improvement, 2.10 [95% CI, 0.10 to 4.06]; P <.001), but the effect size was not clinically meaningful. Conclusions and Relevance Among patients who underwent TAVR, receiving a prescription for a RAS inhibitor at hospital discharge compared with no prescription was significantly associated with a lower risk of mortality and heart failure readmission. However, due to potential selection bias, this finding requires further investigation in randomized trials.

Original languageEnglish
Pages (from-to)2231-2240
Number of pages10
JournalJAMA - Journal of the American Medical Association
Volume320
Issue number21
DOIs
Publication statusPublished - 2018 Dec 4

Fingerprint

Patient Readmission
Angiotensins
Renin
Renin-Angiotensin System
Prescriptions
Heart Failure
Mortality
Stroke Volume
Therapeutics
Transcatheter Aortic Valve Replacement
Ventricular Remodeling
Selection Bias
Medicare
Cardiomyopathies
Health Status
Registries
Cause of Death
Cohort Studies
Retrospective Studies
Quality of Life

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association of Renin-Angiotensin Inhibitor Treatment with Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement. / Inohara, Taku; Manandhar, Pratik; Kosinski, Andrzej S.; Matsouaka, Roland A.; Kosaka, Shun; Mentz, Robert J.; Thourani, Vinod H.; Carroll, John D.; Kirtane, Ajay J.; Bavaria, Joseph E.; Cohen, David J.; Kiefer, Todd L.; Gaca, Jeffrey G.; Kapadia, Samir R.; Peterson, Eric D.; Vemulapalli, Sreekanth.

In: JAMA - Journal of the American Medical Association, Vol. 320, No. 21, 04.12.2018, p. 2231-2240.

Research output: Contribution to journalArticle

Inohara, T, Manandhar, P, Kosinski, AS, Matsouaka, RA, Kosaka, S, Mentz, RJ, Thourani, VH, Carroll, JD, Kirtane, AJ, Bavaria, JE, Cohen, DJ, Kiefer, TL, Gaca, JG, Kapadia, SR, Peterson, ED & Vemulapalli, S 2018, 'Association of Renin-Angiotensin Inhibitor Treatment with Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement', JAMA - Journal of the American Medical Association, vol. 320, no. 21, pp. 2231-2240. https://doi.org/10.1001/jama.2018.18077
Inohara, Taku ; Manandhar, Pratik ; Kosinski, Andrzej S. ; Matsouaka, Roland A. ; Kosaka, Shun ; Mentz, Robert J. ; Thourani, Vinod H. ; Carroll, John D. ; Kirtane, Ajay J. ; Bavaria, Joseph E. ; Cohen, David J. ; Kiefer, Todd L. ; Gaca, Jeffrey G. ; Kapadia, Samir R. ; Peterson, Eric D. ; Vemulapalli, Sreekanth. / Association of Renin-Angiotensin Inhibitor Treatment with Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement. In: JAMA - Journal of the American Medical Association. 2018 ; Vol. 320, No. 21. pp. 2231-2240.
@article{0b77ed3c3d2646f08d2a46331c54a71e,
title = "Association of Renin-Angiotensin Inhibitor Treatment with Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement",
abstract = "Importance Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function. Objective To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR. Design, Setting, and Participants Retrospective cohort study of TAVR procedures performed in the United States (using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry) between July 2014 and January 2016 that were linked to Medicare claims data (final date of follow-up: March 31, 2017). To account for differences in demographics, echocardiographic findings, and in-hospital complications, 1:1 propensity matching was performed. Exposures Initial hospital discharge prescription of a RAS inhibitor after TAVR. Main Outcomes and Measures Primary outcomes were all-cause death and readmission due to heart failure at 1 year after discharge, which were considered separately. The secondary outcome was health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ; score range: 0-100, with a higher score indicating less symptom burden and better quality of life; a small effect size was defined as 5 points) at 1 year. Results Among 21312 patients who underwent TAVR at 417 US sites, 8468 patients (39.7{\%}) were prescribed a RAS inhibitor at hospital discharge. After propensity matching, 15896 patients were included (mean [SD] age, 82.4 [6.8] years; 48.1{\%} were women; mean [SD] left ventricular ejection fraction [LVEF], 51.9{\%} [11.5{\%}]). Patients with a prescription for a RAS inhibitor vs those with no prescription had lower mortality rates at 1 year (12.5{\%} vs 14.9{\%}, respectively; absolute risk difference [ARD], -2.4{\%} [95{\%} CI, -3.5{\%} to -1.4{\%}]; hazard ratio [HR], 0.82 [95{\%} CI, 0.76 to 0.90]) and lower heart failure readmission rates at 1 year (12.0{\%} vs 13.8{\%}; ARD, -1.8{\%} [95{\%} CI, -2.8{\%} to -0.7{\%}]; HR, 0.86 [95{\%} CI, 0.79 to 0.95]). When stratified by LVEF, having a prescription for a RAS inhibitor vs no prescription was associated with lower 1-year mortality among patients with preserved LVEF (11.1{\%} vs 13.9{\%}, respectively; ARD, -2.81{\%} [95{\%} CI, -3.95{\%} to -1.67{\%}]; HR, 0.78 [95{\%} CI, 0.71 to 0.86]), but not among those with reduced LVEF (18.8{\%} vs 19.5{\%}; ARD, -0.68{\%} [95{\%} CI, -3.52{\%} to 2.20{\%}]; HR, 0.95 [95{\%} CI, 0.81 to 1.12]) (P =.04 for interaction). Of 15896 matched patients, 4837 (30.4{\%}) were included in the KCCQ score analysis and improvements at 1 year were greater in patients with a prescription for a RAS inhibitor vs those with no prescription (median, 33.3 [interquartile range, 14.2 to 51.0] vs 31.3 [interquartile range, 13.5 to 51.1], respectively; difference in improvement, 2.10 [95{\%} CI, 0.10 to 4.06]; P <.001), but the effect size was not clinically meaningful. Conclusions and Relevance Among patients who underwent TAVR, receiving a prescription for a RAS inhibitor at hospital discharge compared with no prescription was significantly associated with a lower risk of mortality and heart failure readmission. However, due to potential selection bias, this finding requires further investigation in randomized trials.",
author = "Taku Inohara and Pratik Manandhar and Kosinski, {Andrzej S.} and Matsouaka, {Roland A.} and Shun Kosaka and Mentz, {Robert J.} and Thourani, {Vinod H.} and Carroll, {John D.} and Kirtane, {Ajay J.} and Bavaria, {Joseph E.} and Cohen, {David J.} and Kiefer, {Todd L.} and Gaca, {Jeffrey G.} and Kapadia, {Samir R.} and Peterson, {Eric D.} and Sreekanth Vemulapalli",
year = "2018",
month = "12",
day = "4",
doi = "10.1001/jama.2018.18077",
language = "English",
volume = "320",
pages = "2231--2240",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "21",

}

TY - JOUR

T1 - Association of Renin-Angiotensin Inhibitor Treatment with Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement

AU - Inohara, Taku

AU - Manandhar, Pratik

AU - Kosinski, Andrzej S.

AU - Matsouaka, Roland A.

AU - Kosaka, Shun

AU - Mentz, Robert J.

AU - Thourani, Vinod H.

AU - Carroll, John D.

AU - Kirtane, Ajay J.

AU - Bavaria, Joseph E.

AU - Cohen, David J.

AU - Kiefer, Todd L.

AU - Gaca, Jeffrey G.

AU - Kapadia, Samir R.

AU - Peterson, Eric D.

AU - Vemulapalli, Sreekanth

PY - 2018/12/4

Y1 - 2018/12/4

N2 - Importance Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function. Objective To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR. Design, Setting, and Participants Retrospective cohort study of TAVR procedures performed in the United States (using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry) between July 2014 and January 2016 that were linked to Medicare claims data (final date of follow-up: March 31, 2017). To account for differences in demographics, echocardiographic findings, and in-hospital complications, 1:1 propensity matching was performed. Exposures Initial hospital discharge prescription of a RAS inhibitor after TAVR. Main Outcomes and Measures Primary outcomes were all-cause death and readmission due to heart failure at 1 year after discharge, which were considered separately. The secondary outcome was health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ; score range: 0-100, with a higher score indicating less symptom burden and better quality of life; a small effect size was defined as 5 points) at 1 year. Results Among 21312 patients who underwent TAVR at 417 US sites, 8468 patients (39.7%) were prescribed a RAS inhibitor at hospital discharge. After propensity matching, 15896 patients were included (mean [SD] age, 82.4 [6.8] years; 48.1% were women; mean [SD] left ventricular ejection fraction [LVEF], 51.9% [11.5%]). Patients with a prescription for a RAS inhibitor vs those with no prescription had lower mortality rates at 1 year (12.5% vs 14.9%, respectively; absolute risk difference [ARD], -2.4% [95% CI, -3.5% to -1.4%]; hazard ratio [HR], 0.82 [95% CI, 0.76 to 0.90]) and lower heart failure readmission rates at 1 year (12.0% vs 13.8%; ARD, -1.8% [95% CI, -2.8% to -0.7%]; HR, 0.86 [95% CI, 0.79 to 0.95]). When stratified by LVEF, having a prescription for a RAS inhibitor vs no prescription was associated with lower 1-year mortality among patients with preserved LVEF (11.1% vs 13.9%, respectively; ARD, -2.81% [95% CI, -3.95% to -1.67%]; HR, 0.78 [95% CI, 0.71 to 0.86]), but not among those with reduced LVEF (18.8% vs 19.5%; ARD, -0.68% [95% CI, -3.52% to 2.20%]; HR, 0.95 [95% CI, 0.81 to 1.12]) (P =.04 for interaction). Of 15896 matched patients, 4837 (30.4%) were included in the KCCQ score analysis and improvements at 1 year were greater in patients with a prescription for a RAS inhibitor vs those with no prescription (median, 33.3 [interquartile range, 14.2 to 51.0] vs 31.3 [interquartile range, 13.5 to 51.1], respectively; difference in improvement, 2.10 [95% CI, 0.10 to 4.06]; P <.001), but the effect size was not clinically meaningful. Conclusions and Relevance Among patients who underwent TAVR, receiving a prescription for a RAS inhibitor at hospital discharge compared with no prescription was significantly associated with a lower risk of mortality and heart failure readmission. However, due to potential selection bias, this finding requires further investigation in randomized trials.

AB - Importance Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function. Objective To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR. Design, Setting, and Participants Retrospective cohort study of TAVR procedures performed in the United States (using the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry) between July 2014 and January 2016 that were linked to Medicare claims data (final date of follow-up: March 31, 2017). To account for differences in demographics, echocardiographic findings, and in-hospital complications, 1:1 propensity matching was performed. Exposures Initial hospital discharge prescription of a RAS inhibitor after TAVR. Main Outcomes and Measures Primary outcomes were all-cause death and readmission due to heart failure at 1 year after discharge, which were considered separately. The secondary outcome was health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ; score range: 0-100, with a higher score indicating less symptom burden and better quality of life; a small effect size was defined as 5 points) at 1 year. Results Among 21312 patients who underwent TAVR at 417 US sites, 8468 patients (39.7%) were prescribed a RAS inhibitor at hospital discharge. After propensity matching, 15896 patients were included (mean [SD] age, 82.4 [6.8] years; 48.1% were women; mean [SD] left ventricular ejection fraction [LVEF], 51.9% [11.5%]). Patients with a prescription for a RAS inhibitor vs those with no prescription had lower mortality rates at 1 year (12.5% vs 14.9%, respectively; absolute risk difference [ARD], -2.4% [95% CI, -3.5% to -1.4%]; hazard ratio [HR], 0.82 [95% CI, 0.76 to 0.90]) and lower heart failure readmission rates at 1 year (12.0% vs 13.8%; ARD, -1.8% [95% CI, -2.8% to -0.7%]; HR, 0.86 [95% CI, 0.79 to 0.95]). When stratified by LVEF, having a prescription for a RAS inhibitor vs no prescription was associated with lower 1-year mortality among patients with preserved LVEF (11.1% vs 13.9%, respectively; ARD, -2.81% [95% CI, -3.95% to -1.67%]; HR, 0.78 [95% CI, 0.71 to 0.86]), but not among those with reduced LVEF (18.8% vs 19.5%; ARD, -0.68% [95% CI, -3.52% to 2.20%]; HR, 0.95 [95% CI, 0.81 to 1.12]) (P =.04 for interaction). Of 15896 matched patients, 4837 (30.4%) were included in the KCCQ score analysis and improvements at 1 year were greater in patients with a prescription for a RAS inhibitor vs those with no prescription (median, 33.3 [interquartile range, 14.2 to 51.0] vs 31.3 [interquartile range, 13.5 to 51.1], respectively; difference in improvement, 2.10 [95% CI, 0.10 to 4.06]; P <.001), but the effect size was not clinically meaningful. Conclusions and Relevance Among patients who underwent TAVR, receiving a prescription for a RAS inhibitor at hospital discharge compared with no prescription was significantly associated with a lower risk of mortality and heart failure readmission. However, due to potential selection bias, this finding requires further investigation in randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=85058472691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058472691&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.18077

DO - 10.1001/jama.2018.18077

M3 - Article

VL - 320

SP - 2231

EP - 2240

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 21

ER -